Fung

MODERN PHARMACEUTICS

GILBERT S. BANKER

Industrial and Physical Pharmacy Department Purdue University West Lafayette, Indiana

CHRISTOPHER T. RHODES


Department of Pharmacy University of Rhode Island Kingston, Rhode Island

MARCEL DEKKER, INC. New York and Basel

CLASS SEP.

Δ

Find authenticated court documents without watermarks at docketalarm.com.



«45.00

Library of Congress Cataloging in Publication Data Main entry under title:

Modern pharmaceutics.

(Drugs and the pharmaceutical sciences; v. 7) Includes indexes.
1. Drugs—Dosage forms. 2. Pharmacology.
3. Drug trade—Quality control. I. Banker, Gilbert S. [date] II. Rhodes, Christopher T. [date]
RS201.A2M62 615'.1 79-18742
ISBN 0-8247-6833-7

COPYRIGHT © 1979 by MARCEL DEKKER, INC. ALL RIGHTS RESERVED

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

MARCEL DEKKER, INC. 270 Madison Avenue, New York, New York 10016

Current printing (last digit): 10 9 8 7 6 5 4 3 2 1

DOCKE

PRINTED IN THE UNITED STATES OF AMERICA

Chapter 7

CHEMICAL KINETICS AND DRUG STABILITY

Ho-Leung Fung

Department of Pharmaceutics State University of New York at Buffalo Amherst, New York

	•	
I.	INTRODUCTION	227
п.	MODES OF PHARMACEUTICAL DEGRADATION	228
	A. Chemical Degradative Routes	229
	B. Physical Degradative Routes	235
пі.	QUANTITATION OF RATE OF DEGRADATION	238
	A. Kinetic Equations	239
	B. Energetics of Reactions	2 44
IV.	THE ARRHENIUS EQUATION AND ACCELERATED	
	STABILITY TESTING	246
v.	FACTORS AFFECTING REACTION RATE	2 4 9
	A. pH	249
	B. Solvent	253
	C. Solubility	257
	D. Additives	257
	E. Other Factors	259
	REFERENCES	25 9

I. INTRODUCTION

In any rational design and evaluation of dosage forms for drugs, the stability of the active component must be a major criterion in determining acceptance or rejection of trial formulations. There are several forms of instability which can lead to rejection of a drug product. First, there may be extensive chemical degradation of the active drug, leading to a substantial lowering of the quantity of the therapeutic agent in the dosage form. With the rapid advance of medicinal chemistry, drugs have become increasingly more potent and a number of them now have very narrow therapeutic ranges. Drugs like nitroprusside, digoxin, theophylline, and others leed to be carefully titrated in individual patients so that serum levels are neither 30 high as to be potentially toxic nor so low as to be ineffective. In these cases, it s of paramount importance that the drug dosage form can reproducibly deliver the ame amount of drug. Second, although chemical degradation of the active drug nay not be extensive, a very toxic product may be formed in the decomposition process. Dearborn [1] described a number of examples in which the products of legradation are significantly more toxic than the original therapeutic agent. Thus, he conversions of tetracycline to epianhydrotetracycline, arsphenamine to

227

DOCKE

Find authenticated court documents without watermarks at docketalarm.com.

FUNG

Mapharsen, and p-aminosalicylic acid to m-aminophenol in dosage forms give rise to potentially toxic agents which, when ingested, can cause undesirable effects. Third, with the development of analytical methodologies which allow for precise measurements of blood levels of drugs, we learn about the problem of bioavailability. (This topic has been extensively dealt with in Chapters 2 through 6.) Instability of a drug product can be exhibited by a decrease in its bioavailability, rather than by loss of drug or production of toxic degradation products. This reduction in bioavailability can lead to a substantial lowering in the therapeutic efficacy of the dosage form. This phenomenon can be brought about by physical and/or chemical changes of the diluents in the dosage form, independent of whatever changes the active drug may have undergone. A more detailed discussion of this phenomenon will be given later in Section II.B.3. Fourth, there may be substantial changes in the physical appearance of the dosage form. Examples of these physical changes include mottling of tablets, creaming of emulsions, or caking of suspensions. Although the therapeutic efficacy of the dosage form may be unaffected by these changes, the patient will most likely lose confidence in the drug product, which then has to be rejected.

A drug product, therefore, has to satisfy stability criteria <u>chemically</u>, <u>physically</u>, <u>therapeutically</u>, and <u>toxicologically</u>. Basic principles in pharmaceutical kinetics can often be applied to anticipate and quantify the undesirable changes so that they can be circumvented by stabilization techniques. In the present chapter, stability problems and examples are discussed from the viewpoint of the research and development scientist. The presentation follows the following sequence: first, an overview of the potential routes of degradation that drug molecules can undergo; then, a discussion of the mathematics used to quantify drug degradation; and, finally, a discussion of the factors which can affect degradation rates, with an emphasis on stabilization techniques. It is not the intent of this chapter to document stability data for the various drugs. Readers are referred to a classic chapter on stability of drugs by Garrett [2] and a more recent compilation by Lintner [3] for this information.

II. MODES OF PHARMACEUTICAL DEGRADATION

Since most drugs are organic molecules, it is important to first recognize that most pharmaceutical degradations are, in principle, similar to reactions described for organic compounds in standard organic chemistry textbooks. On the other hand it is also important to realize that different emphases are placed on the type of reactions which are commonly encountered in drug product stability as opposed to those seen in classical organic chemistry. In the latter case, reactions are generally described for the purpose of synthesis; thus the conditions under which they are carried out are most likely to be quite drastic. Reactive agents, e.g., thionyl chloride or lithium aluminum hydride, are employed in relatively high concentrations (usually > 10%) and are treated at exaggerated conditions such as refluxing. Reactions are effected in relatively short periods of time (hours or days). In contrast, pharmaceutical reactions pertaining to drug product stability usually involve the active drug components in relatively dilute concentrations. For example, dexamethasone sodium phosphate, a synthetic adrenocortical steroid salt, is

This material may be protected by Copyright law (Title 17 U.S. Code)

DOCKET

CHEMICAL KINETICS AND DRUG STABILITY

present only to the extent of about 0.01% in its elixir, 0.4% in its injection, 0.1% in its cream, and 0.05% in its ophthalmic ointment. The decomposition of a drug is more likely to be mediated not through reaction with another active ingredient but through reaction with comparatively inert environmental chemicals or stimuli such as water, oxygen, or light. Reaction conditions are usually ambient and sometimes even at refrigerated temperatures. The durations for pharmaceutical reactions are in terms of months or years as opposed to hours or days in synthetic organic chemistry.

Students need to refocus their experiences on chemical reactions learned from organic chemistry classes. Reactions such as the Diels-Alder reaction and aldol condensations, which are important in synthetic and mechanistic organic chemistry, are of only minor importance when drug degradation is concerned. On the other hand, hydrolysis, oxidation, and photolysis reactions constitute some of the most important modes of pharmaceutical degradation.

Appreciation of reactions of particular functional groups is important if we are to gain a broader view of drug degradation. It is difficult, and perhaps impossible, to remember degradative pathways of all commonly used drugs. By utilizing some functional group chemistry, it is possible to anticipate the potential mode(s) of degradation which the drug molecule will likely undergo. The following discussion, therefore, is mainly oriented, where possible, to describing drug degradative modes through indentification of the reactive functional groups in the drug molecule. The degradative routes are described, through the use of selected examples, as <u>chemical</u>, when new chemical entities are formed as a result of drug degradation, and as <u>physical</u>, when drug loss does not produce distinctly different chemical products.

A. Chemical Degradative Routes

1. Solvolysis

DOCKET

This type of reaction involves the decomposition of the active drug through reaction with the solvent present. In most instances the solvent is water; but in some cases the reaction may involve pharmaceutical cosolvents such as ethyl alcohol or polyethylene glycol. These solvents act as nucleophilic agents, and they attack electropositive centers in the drug molecule. The commonest solvelysis reactions encountered in drug instability are those involving "labile" carbonyl compounds such as esters, lactones, and lactams (Table 7.1).

Although all the functional groups cited are in principle subjected to solvolysis, the rates at which they undergo this reaction may be vastly different. For example, the rate of hydrolysis of a β -lactam ring (a cyclized amide) is very much aster than that of its linear analog. The half-life (the time needed for half the ^{lrug} to decompose) of the β -lactam in potassium phenethicillin at 35°C and pH 1.5 s about 1 hr. A corresponding value for penicillin G is about 4 min [4]. By Omparison, the half-life of propionamide at 0.18 molal H₂SO₄ and at 25°C is Dout 58 hr [5]. The extreme susceptibility of the penicillin group toward hydrolys is due to the high degree of steric strain in the 4-membered β -lactam ring.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.